

Supplementary Table 3. Clinical outcomes

LDL-C	Tegoprazan (n = 107)	PPI (n = 155)	Univariable		Multivariable ^{a)}		IPTW	
			HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
All death	1 (0.9)	1 (0.6)	1.56 (0.10–24.92)	0.754	-	-	1.96 (0.35–10.87)	0.441
Cardiac death	0 (0.0)	1 (0.6)	-	-	-	-	-	-
All MI	0 (0.0)	0 (0.0)	-	-	-	-	-	-
TV-MI	0 (0.0)	0 (0.0)	-	-	-	-	-	-
Any revascularization	2 (1.9)	2 (1.3)	1.77 (0.25–12.64)	0.569	0.85 (0.06–12.88)	0.905	1.29 (0.30–5.63)	0.730
TVR	1 (0.9)	1 (0.6)	1.66 (0.10–26.59)	0.719	-	-	0.74 (0.07–7.82)	0.802
Stent thrombosis	0 (0.0)	0 (0.0)	-	-	-	-	-	-
Stroke	0 (0.0)	1 (0.6)	-	-	-	-	-	-
Any bleeding	0 (0.0)	1 (0.6)	-	-	-	-	-	-
GI bleeding	0 (0.0)	1 (0.6)	-	-	-	-	-	-

Values are presented as frequency (%).

PPI, proton-pump inhibitor; IPTW, inverse probability of treatment weight; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; TV-MI, target vessel myocardial infarction; TVR, target vessel revascularization; GI, gastrointestinal; BMI, body mass index; CKD, chronic kidney disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery.

^{a)}Multivariable are weighted covariates by using treatment, sex, age, BMI, clinical presentation, smoking, hypertension, diabetes mellitus, dyslipidemia, CKD, prior stroke, prior MI and prior PCI/CABG.